No connection

Search Results

ABBV vs ACON

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ACON
Aclarion, Inc.
BEARISH
Price
$3.33
Market Cap
$3.5M
Sector
Healthcare
AI Confidence
92%

Valuation

P/E Ratio
ABBV
163.63
ACON
--
Forward P/E
ABBV
15.42
ACON
-0.24
P/B Ratio
ABBV
-146.66
ACON
0.16
P/S Ratio
ABBV
6.5
ACON
52.03
EV/EBITDA
ABBV
15.27
ACON
1.38

Profitability

Gross Margin
ABBV
71.46%
ACON
-7.83%
Operating Margin
ABBV
35.5%
ACON
-9666.16%
Profit Margin
ABBV
4.0%
ACON
0.0%
ROE
ABBV
137.96%
ACON
-97.72%
ROA
ABBV
9.59%
ACON
-52.37%

Growth

Revenue Growth
ABBV
9.1%
ACON
31.5%
Earnings Growth
ABBV
-88.7%
ACON
--

Financial Health

Debt/Equity
ABBV
--
ACON
--
Current Ratio
ABBV
0.72
ACON
17.01
Quick Ratio
ABBV
0.47
ACON
16.31

Dividends

Dividend Yield
ABBV
3.05%
ACON
--
Payout Ratio
ABBV
490.15%
ACON
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ACON BEARISH

ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.

Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent 1-month price increase (+22.9%) shows short-term momentum
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational health
Negative operating margin (-9666.16%) and ROE (-97.72%) reflect systemic profitability collapse
Price/Sales of 52.03 is unsustainable and far exceeds peer averages (avg: ~185.39 P/E, but negative margins suggest no valid comparison)

Compare Another Pair

ABBV vs ACON: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Aclarion, Inc. (ACON) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile